T Cell Lymphomas
News
CPI-613 receives orphan designation for PTCL
The Food and Drug Administration has granted orphan drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma (PTCL).
[[{"...
Article
Make The Diagnosis - September 2018
A 75-year-old man presented with asymptomatic annular plaques on both arms, thighs, abdomen, and buttocks, present for several months.
Conference Coverage
New regimens for youth with T-cell malignancies yield best outcomes yet
More than 8 in 10 youth were still alive and free of disease 4 years after starting combinations of methotrexate and/or nelarabine with chemo.
News
FDA places partial hold on trials after secondary lymphoma
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.
Conference Coverage
VIDEO: How to prepare PTCL patients for transplant
LA JOLLA, CALIF. – Dr. Steven Horwitz says the key to preparing patients for transplant is “good remission.”
News
FDA updates breast implant–associated lymphoma cases, risk
Estimates on the lifetime risk vary widely.
CME
The Long and Winding Road: PTCL 10 Years from Now
Conference Coverage
Best options for treating relapsed/refractory PTCL
LA JOLLA, CALIF. – Hematologists from the Royal Marsden Hospital in London review their best practices for the hardest to treat PTCL cases.
Conference Coverage
Mycosis fungoides increases risk for second cancers
LA JOLLA, CALIF. – The study mines data from the SEER-18 database.
Conference Coverage
Basiliximab/BEAM may improve post-ASCT outcomes in PTCL
LA JOLLA, CALIF. – The phase 1 trial is testing the use of a CD25 monoclonal antibody for achieving long-term remission in PTCL.
Conference Coverage
A view from the bridge to transplant for PTCL
LA JOLLA, CALIF. – Subtype and timing matter when considering the best bridge to transplant.